5.19

4.22% 0.21

After Hours: 5.21 0.02 +0.39%

Vanda Pharmaceuticals Inc (VNDA)

Overview News Price History Option Chain Financials Discussions Forecast

Vanda Pharmaceuticals Inc stock is traded at $5.19, with a volume of 829.83K. It is up +4.22% in the last 24 hours and up +14.07% over the past month. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Previous Close:

$4.98

Open:

$5.04

24h Volume:

829.83K

Relative Volume:

1.36

Market Cap:

$290.37M

Revenue:

$192.64M

Net Income/Loss:

$2.51M

P/E Ratio:

19.22

EPS:

0.27

Net Cash Flow:

$12.42M

1W Performance:

+5.92%

1M Performance:

+14.07%

6M Performance:

-0.76%

1Y Performance:

+45.79%

1-Day Range:

$5.0101

$5.42

1-Week Range:

$4.83

$5.42

52-Week Range:

$3.46

$6.75

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name

Vanda Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

202-734-3400

Address

2200 PENNSYLVANIA AVE NW, WASHINGTON

Employee

203

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

VNDA's Discussions on Twitter

Compare VNDA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNDA Vanda Pharmaceuticals Inc	5.19	290.37M	192.64M	2.51M	12.42M	0.27
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-31-24	Initiated	H.C. Wainwright	Buy
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight
Feb-25-22	Downgrade	Jefferies	Buy → Hold
May-12-21	Initiated	BofA Securities	Buy
Jan-14-21	Downgrade	Citigroup	Buy → Neutral
Oct-29-20	Upgrade	Citigroup	Neutral → Buy
Jun-09-20	Downgrade	Citigroup	Buy → Neutral
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy
Nov-07-19	Downgrade	Citigroup	Buy → Neutral
Aug-01-19	Upgrade	Citigroup	Neutral → Buy
Jul-25-19	Downgrade	Stifel	Buy → Hold
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Sep-14-17	Reiterated	Piper Jaffray	Overweight
Jun-27-17	Resumed	Piper Jaffray	Overweight
May-26-17	Initiated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Oppenheimer	Outperform
Nov-09-16	Initiated	Aegis Capital	Buy
Oct-06-16	Resumed	Jefferies	Buy

View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

Nov 26, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve

Nov 26, 2024

Nov 25, 2024

StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Nov 25, 2024

Nov 19, 2024

Long Term Trading Analysis for (VNDA) - Stock Traders Daily

Nov 19, 2024

Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com Canada

Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India

Nov 18, 2024

Nov 17, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Nov 17, 2024

Nov 14, 2024

New Strong Buy Stocks For November 14th - Barchart

Nov 14, 2024

Nov 13, 2024

Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria

Nov 13, 2024

Nov 12, 2024

Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan

Nov 12, 2024

BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Nov 12, 2024

Nov 09, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat

Nov 09, 2024

Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India

Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia

Nov 08, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 07, 2024